



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Cwm Taf Morgannwg
University Health Board



Freedom of Information Request: Our Reference CTMUHB_321_24

You asked:

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) in three months from the start of Jan 2024 to the end of Mar 2024 (or the latest available 3 months).

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Q1 – How many patients were treated with the following drugs from the following departments (for any disease) from the start of Jan 2024 to the end of Mar 2024? Please use the latest available 3 months if January to March is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)			
Adalimumab (Biosimilars)			
Apremilast			
Bimekizumab			
Brodalumab			
Certolizumab Pegol			
Deucravacitinib			
Etanercept (Enbrel)			
Etanercept (Biosimilars)			
Guselkumab			
Infliximab (Remicade)			
Infliximab (Biosimilars)			
Ixekizumab			
Risankizumab			
Secukinumab			
Tildrakizumab			
Ustekinumab			
Upadacitinib			
Vedolizumab			
Filgotinib			
Golimumab			
Mirikizumab			
Ozanimod			
Tofacitinib			
Baricitinib			
Rituximab			
Sarilumab			
Tocilizumab			

Our response:

Please find below as requested the table populated with the information Medicines Management are able to provide at this current time. The period the data relates to is 1st January 24 to 31st March 24 the latest 3 months available.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	**	6	69
Adalimumab (Biosimilars)	53	177	404
Apremilast	68	0	16
Bimekizumab	21	0	**
Brodalumab	**	0	0
Certolizumab Pegol	**	**	61
Deucravacitinib	**	0	0
Etanercept (Enbrel)	0	0	24
Etanercept (Biosimilars)	**	0	295
Guselkumab	23	0	**
Infliximab (Remicade)	**	**	**
Infliximab (Biosimilars)	**	199	22
Ixekizumab	19	0	19
Risankizumab	51	10	0
Secukinumab	9	0	91
Tildrakizumab	11	0	0
Ustekinumab	34	175	16
Upadacitinib	12	20	14
Vedolizumab	0	183	0
Filgotinib	0	**	5
Golimumab	0	0	61
Mirikizumab	0	0	0
Ozanimod	0	0	0
Tofacitinib	0	**	11
Baricitinib	**	0	41
Rituximab	0	0	32
Sarilumab	0	0	**
Tocilizumab	0	0	100

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful

processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.